Funding
Funding not disclosed
Founders
Product
Problem
Current methods for detecting cancer in companion animals often rely on invasive procedures or may not be effective in early stages. This can lead to delayed diagnosis and treatment, reducing the chances of successful outcomes for pets with cancer.
Solution
Medical Ark offers Ark-Test, a liquid biopsy system designed for early cancer detection in dogs using a simple blood draw. By analyzing microRNAs within exosomes secreted by tumor cells, the system aims to identify cancer at an earlier stage than traditional methods. This non-invasive approach allows for frequent monitoring and can improve the efficacy of existing cancer treatments, ultimately increasing the survival rates and quality of life for companion animals. The test helps veterinarians make informed decisions about treatment plans and monitor disease progression with minimal stress to the animal.
Target Audience
The primary target audience includes veterinarians and animal hospitals seeking advanced diagnostic tools for early cancer detection in canine patients, as well as pet owners concerned about their companion animal's health.
Features
- Utilizes microRNA analysis from exosomes for cancer detection
- Requires only a small blood sample, minimizing invasiveness
- Designed for early-stage cancer detection in dogs
- Provides data to assist veterinarians in treatment planning and monitoring